These ex vivo studies are consistent with our prior results where combined PD-1 and CCR2 blockade led to decreased numbers of exhausted CD4+ and CD8+ T cells and increased IFN-γ expression within the gliomas. The gene discussed is CD4; the disease is central nervous system cancer.